Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.

Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, Hogg A, Liyanage HD, Dorie MJ, Brown JM, Denny WA, Hay MP, Wilson WR.

Clin Cancer Res. 2010 Oct 15;16(20):4946-57. doi: 10.1158/1078-0432.CCR-10-1439. Epub 2010 Aug 20.

2.

Renal oxygenation suppresses VHL loss-induced senescence that is caused by increased sensitivity to oxidative stress.

Welford SM, Dorie MJ, Li X, Haase VH, Giaccia AJ.

Mol Cell Biol. 2010 Oct;30(19):4595-603. doi: 10.1128/MCB.01618-09. Epub 2010 Aug 2.

3.

Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment.

Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A, Brown JM.

Proc Natl Acad Sci U S A. 2010 May 4;107(18):8363-8. doi: 10.1073/pnas.0911378107. Epub 2010 Apr 19.

4.

DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.

Singleton RS, Guise CP, Ferry DM, Pullen SM, Dorie MJ, Brown JM, Patterson AV, Wilson WR.

Cancer Res. 2009 May 1;69(9):3884-91. doi: 10.1158/0008-5472.CAN-08-4023. Epub 2009 Apr 14.

5.

Association of reactive oxygen species levels and radioresistance in cancer stem cells.

Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL, Clarke MF.

Nature. 2009 Apr 9;458(7239):780-3. doi: 10.1038/nature07733.

6.

Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104.

Liu SC, Ahn GO, Kioi M, Dorie MJ, Patterson AV, Brown JM.

Cancer Res. 2008 Oct 1;68(19):7995-8003. doi: 10.1158/0008-5472.CAN-08-1698.

7.

DNA damage during reoxygenation elicits a Chk2-dependent checkpoint response.

Freiberg RA, Hammond EM, Dorie MJ, Welford SM, Giaccia AJ.

Mol Cell Biol. 2006 Mar;26(5):1598-609.

8.

Inhibition of ATR leads to increased sensitivity to hypoxia/reoxygenation.

Hammond EM, Dorie MJ, Giaccia AJ.

Cancer Res. 2004 Sep 15;64(18):6556-62.

9.

Genome-wide identification of genes conferring resistance to the anticancer agents cisplatin, oxaliplatin, and mitomycin C.

Wu HI, Brown JA, Dorie MJ, Lazzeroni L, Brown JM.

Cancer Res. 2004 Jun 1;64(11):3940-8.

10.

Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients.

Le QT, Kovacs MS, Dorie MJ, Koong A, Terris DJ, Pinto HA, Goffinet DR, Nowels K, Bloch D, Brown JM.

Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):375-83.

PMID:
12738312
11.

ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation.

Hammond EM, Dorie MJ, Giaccia AJ.

J Biol Chem. 2003 Apr 4;278(14):12207-13. Epub 2003 Jan 7.

12.

Estimating DNA repair by sequential evaluation of head and neck tumor radiation sensitivity using the comet assay.

Terris DJ, Ho EY, Ibrahim HZ, Dorie MJ, Kovacs MS, Le QT, Koong AC, Pinto HA, Brown JM.

Arch Otolaryngol Head Neck Surg. 2002 Jun;128(6):698-702.

PMID:
12049567
13.

Effect of blood transfusion in an experimental sarcoma model.

Lin HS, Samy RN, Lum J, Dorie MJ, Terris DJ.

Arch Otolaryngol Head Neck Surg. 2002 Mar;128(3):308-12.

PMID:
11886349
14.

Hypoxia links ATR and p53 through replication arrest.

Hammond EM, Denko NC, Dorie MJ, Abraham RT, Giaccia AJ.

Mol Cell Biol. 2002 Mar;22(6):1834-43.

15.

Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine.

Wouters BG, Delahoussaye YM, Evans JW, Birrell GW, Dorie MJ, Wang J, MacDermed D, Chiu RK, Brown JM.

Cancer Res. 2001 Jan 1;61(1):145-52.

16.

DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.

Dorie MJ, Kovacs MS, Gabalski EC, Adam M, Le QT, Bloch DA, Pinto HA, Terris DJ, Brown JM.

Neoplasia. 1999 Nov;1(5):461-7.

17.

Oxygen tension measurements of tumors growing in mice.

Adam MF, Dorie MJ, Brown JM.

Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):171-80.

PMID:
10477021
19.

1,2,4-Benzotriazine 1,4-dioxides. An important class of hypoxic cytotoxins with antitumor activity.

Kelson AB, McNamara JP, Pandey A, Ryan KJ, Dorie MJ, McAfee PA, Menke DR, Brown JM, Tracy M.

Anticancer Drug Des. 1998 Sep;13(6):575-92.

PMID:
9755719
20.

Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia.

Siim BG, Menke DR, Dorie MJ, Brown JM.

Cancer Res. 1997 Jul 15;57(14):2922-8.

21.
22.

Interleukin 1 increases thymidine labeling index of normal tissues of mice but not the tumor.

Zaghloul MS, Dorie MJ, Kallman RF.

Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):805-11.

PMID:
8040027
23.
24.
25.

Interleukin-1 modulatory effect on the action of chemotherapeutic drugs and localized irradiation of the lip, duodenum, and tumor.

Zaghloul MS, Dorie MJ, Kallman RF.

Int J Radiat Oncol Biol Phys. 1993 Jun 15;26(3):417-25.

PMID:
8514539
26.

Reoxygenation in the RIF-1 tumor after chemotherapy.

Dorie MJ, Kallman RF.

Int J Radiat Oncol Biol Phys. 1992;24(2):295-9.

PMID:
1382047
27.

Protection by interleukin 1 against lung toxicity caused by cyclophosphamide and irradiation.

Dorie MJ, Bedarida G, Kallman RF.

Radiat Res. 1991 Dec;128(3):316-9.

PMID:
1961929
28.

Interleukin-1 modification of the effects of cyclophosphamide and fractionated irradiation.

Dorie MJ, Kallman RF, Cebulska-Wasilewska A.

Int J Radiat Oncol Biol Phys. 1991 Feb;20(2):311-4.

PMID:
1991694
29.

Interleukin 1 protects against the lethal effects of irradiation of mice but has no effect on tumors in the same animals.

Dorie MJ, Allison AC, Zaghloul MS, Kallman RF.

Proc Soc Exp Biol Med. 1989 May;191(1):23-9.

PMID:
2654945
30.

Reoxygenation of the RIF-1 tumor after fractionated radiotherapy.

Dorie MJ, Kallman RF.

Int J Radiat Oncol Biol Phys. 1986 Oct;12(10):1853-9.

PMID:
3759537
31.
32.

Tumor oxygenation and reoxygenation during radiation therapy: their importance in predicting tumor response.

Kallman RF, Dorie MJ.

Int J Radiat Oncol Biol Phys. 1986 Apr;12(4):681-5.

PMID:
3700172
33.

Reoxygenation in the RIF-1 tumor.

Dorie MJ, Kallman RF.

Int J Radiat Oncol Biol Phys. 1984 May;10(5):687-93.

PMID:
6735757
34.

Migration and internalization of cells and polystyrene microsphere in tumor cell spheroids.

Dorie MJ, Kallman RF, Rapacchietta DF, Van Antwerp D, Huang YR.

Exp Cell Res. 1982 Sep;141(1):201-9. No abstract available.

PMID:
7117414
35.

Successful murine tumor allotransplantation after total lymphoid irradiation.

Hoppe RT, Dorie MJ.

J Immunol. 1982 Jun;128(6):2387-9.

PMID:
7042838
36.

Turnover of circulating hematopoietic stem cells.

Dorie MJ, Maloney MA, Patt HM.

Exp Hematol. 1979 Oct;7(9):483-9.

PMID:
527693
37.

Hematopoietic stem cell regulatory volumes as revealed in studies of the bgj/bgj:W/WV chimera.

Maloney MA, Dorie MJ, Lamela RA, Rogers ZR, Patt HM.

J Exp Med. 1978 Apr 1;147(4):1189-97.

38.

Concentration gradient of blood stem cells in mouse bone marrow--an open question.

Maloney MA, Lamela RA, Dorie MJ, Patt HM.

Blood. 1978 Mar;51(3):521-5.

PMID:
623912

Supplemental Content

Loading ...
Support Center